Sign Up Today and Learn More About Cambrian Biopharma Stock
Invest in or calculate the value of your shares in Cambrian Biopharma or other pre-IPO companies through EquityZen's platform.
Cambrian Biopharma Stock (CAMB)
Cambrian is a distributed development company building therapeutics to lengthen health span.
About Cambrian Biopharma Stock
Founded
2019
Headquarters
New York, NY, US
Industries
Science and Engineering, Health Care, Biotechnology
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
Cambrian Biopharma Press Mentions
Stay in the know about the latest news on Cambrian Biopharma
Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award
prnewswire • Apr 24, 2024
From Longevity To Aging In Place, These Are The Top Areas For Senior-Focused Startups
news • Dec 14, 2023
Hear how Cambrian BioPharma is reinventing drug (and drug company) development
TechCrunch • May 03, 2023
Hear how Cambrian BioPharma is reinventing drug (and drug company) development
TechCrunch • Apr 26, 2023
Cambrian Bio Appoints Health Policy Veteran Adrienne Hallett as Vice President of Global Policy and Strategic Initiatives
biospace • Mar 20, 2023
Cambrian Biopharma Management
Leadership team at Cambrian Biopharma
Board Member
Martin Chavez
Executive Vice President, Chemistry
Dennis Yamashita
Join now and verify your accreditation status to gain access to:
- Cambrian Biopharma current valuation
- Cambrian Biopharma stock price
- Available deals in Cambrian Biopharma and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Cambrian Biopharma Stock
How to invest in Cambrian Biopharma stock?
Accredited investors can buy pre-IPO stock in companies like Cambrian Biopharma through EquityZen funds. These investments are made available by existing Cambrian Biopharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Cambrian Biopharma stock?
Shareholders can sell their Cambrian Biopharma stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."